Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 4
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03991000Phase 3Terminated

Iron in Patients With Cardiovascular Disease

Role: lead

NCT03820466Phase 3Terminated

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Role: lead

NCT03989505Completed

Proenkephalin for Prediction of Contrast-Associated Kidney Events

Role: lead

NCT03989531Phase 2Completed

Adrecizumab in Cardiogenic Shock

Role: lead

NCT03995277Phase 4Completed

Effect of Biotin on Routine Laboratory Values

Role: lead

All 5 trials loaded